ArticleFrontiers in oncology2024
Stereotactic central/core ablative radiation therapy: results of a phase I study of a novel strategy to treat bulky tumor.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06987370 (A Phase II Randomized Controlled Clinical Study on the Efficacy and Safety Evaluation of Radiotherapy Mode Based on SFRT and SCART Technologies for Bone Metastatic Malignant Tumors With Soft Tissue Formation), which is not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Randomized Controlled Clinical Study on the Efficacy and Safety Evaluation of Radiotherapy Mode Based on SFRT and SCART Technologies for Bone Metastatic Malignant Tumors With Soft Tissue Formation
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Bibliometric analysis of global research trends in spatially fractionated radiotherapy.Frontiers in oncology · 2026Pooled it
- Preliminary results from a phase II trial of spatially fractionated radiotherapy combined with immunotherapy and anti-angiogenic therapy in patients with bulky solid tumors: early evidence of promising efficacy and favorable safety.Radiation oncology (London, England) · 2026Trial
- C-X-C Motif Chemokine Receptor 4 (CXCR4)-Targeted Biologically Guided Proton Spatially Fractionated Radiotherapy for Bulky Limited-Stage Small Cell Lung Cancer.Precision radiation oncology · 2026Article
- A geometry-based scaling model for stereotactic treatment volume definition in stereotactic centralized ablative radiation therapy.Journal of applied clinical medical physics · 2026Article
- A dosimetric study of photon energy and flattening filter mode combinations in Stereotactic Central Ablative Radiotherapy.Journal of applied clinical medical physics · 2026Article
- Polar-coordinated contour processing algorithm in optimizing SCART treatment volume.Frontiers in oncology · 2026Article
- SFRT alleviates symptoms associated with bulky advanced cancer: a retrospective single-center cohort analysis.Frontiers in oncology · 2026Article
- SCART sequential lattice spatial fractionated radiotherapy combined with chemotherapy for recurrent ovarian cancer with bulky bone metastasis: a case report.Frontiers in oncology · 2026Article
- Rapid Hemostasis and Significant Tumor Regression in Ulcerative Breast Cancer Via Combined Modified Lattice Radiotherapy and Systemic Therapy: A Case Report.Breast cancer : basic and clinical research · 2026Article
- Complete response of a giant metastatic neck mass in tonsillar squamous cell carcinoma achieved with radiotherapy combined with immunotherapy: a case report.Frontiers in oncology · 2026Article
- Stereotactic centralized ablative radiation therapy: a framework for ultra-heterogeneous radiotherapy of bulky tumors.Frontiers in oncology · 2026Article
- Efficacy and safety evaluation of radiotherapy approach based on spatially fractionated radiotherapy and stereotactic core ablative radiation therapy technologies for bone metastatic malignant tumors with soft tissue formation: A randomized controlled phase II trial.Precision radiation oncology · 2025Article
- Partially Ablative Radiotherapy for Bulky Tumors: A Narrative Review of a Developing Concept.Journal of personalized medicine · 2025Review
- Interim Analysis of Pro-Grid: A Phase 1 Proton Spatially Fractionated Radiation Therapy Trial.Advances in radiation oncology · 2025Article
- Article
- Demonstration of an enhanced dosing pattern for debulking large and bulky unresectable tumors via differential hole-size spatially fractionated radiotherapy.Journal of applied clinical medical physics · 2025Article
- Spatially fractionated radiation therapy for treating recurrent glioblastoma: a dosimetric feasibility study.Frontiers in oncology · 2025Article
- Proton stereotactic centralized ablative radiation therapy for treating bulky tumor: a treatment plan study.Frontiers in oncology · 2025Article
- Stereotactic core ablative radiation therapy for small hypoxic tumors: impact of dosimetric approaches and consequent optimization strategy in the context of spatially fractionated radiation therapy.Frontiers in oncology · 2025Article
- Central-boost Ablative Radiation Therapy for Solid Tumors: Study Protocol of a Single-arm, Phase II Trial (CBART).Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Bulky tumor remains as a challenge to surgery, chemotherapy and conventional radiation therapy. Hence, in efforts to overcome this challenge, we designed a novel therapeutic paradigm via strategy of Stereotactic Central/Core Ablative Radiation Therapy (SCART).), which is based on the principles of SBRT (stereotactic body radiation therapy and spatially fractionated radiation therapy (SFRT). We intend to safely deliver an ablative dose to the core of the tumor and with a low dose at tumor edge. The purpose of the phase 1 study was to determine dose-limiting toxicities (DLT)s and the Maximum Tolerated Dose (MTD) of SCART. Methods and materials: We defined a SCART-plan volume inside the tumor, which is proportional to the dimension of tumor. VMAT/Cyberknife technique was adopted. In the current clinical trial; Patients with biopsy proven recurrent or metastatic bulky cancers were enrolled. The five dose levels were 15 Gy X1, 15Gy X3, 18GyX3, 21GyX3 and 24GyX3, while keeping the whole tumor GTV's border dose at 5Gy each fraction. There was no restriction on concurrent systemic chemotherapy agents. Results: 21 patients were enrolled and underwent SCART. All 21 patients have eligible data for study follow-up. Radiotherapy was well tolerated with all treatment completed as scheduled. The dose was escalated for two patients to 24GyX3. No grade 3 or higher toxicity was observed in any of the enrolled patients. The average age of patients was 66 years (range: 14 Conclusion: SCART was safely escalated to 24 GyX 3 fractions, which is the maximum Tolerated Dose (MTD) for SCART. This regimen will be used in future phase II trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.